This is a working overview of peptide research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
== Membrane separation processes == Membrane separation processes have a very important role in the separation industry. Nevertheless, they were not considered technically important until the mid-1970s. Membrane separation processes differ based on separation mechanisms and size of the separated particles. The widely used membrane processes include microfiltration, ultrafiltration, nanofiltration, reverse osmosis, electrolysis, dialysis, electrodialysis, gas separation, vapor permeation, pervaporation, membrane distillation, and membrane contactors. All processes except for pervaporation involve no phase change. All processes except electrodialysis are pressure driven. Microfiltration and ultrafiltration is widely used in food and beverage processing (beer microfiltration, apple juice ultrafiltration), biotechnological applications and pharmaceutical industry (antibiotic production, protein purification), water purification and wastewater treatment, the microelectronics industry, and others. Nanofiltration and reverse osmosis membranes are mainly used for water purification purposes. Dense membranes are utilized for gas separations (removal of CO2 from natural gas, separating N2 from air, organic vapor removal from air or a nitrogen stream) and sometimes in membrane distillation. The later process helps in the separation of azeotropic compositions reducing the costs of distillation processes.
She trained at the London Academy of Music and Dramatic Art and her stage work has included appearances with the National Theatre and the Royal Shakespeare Company. She was made a dame in the 2020 Queen's Birthday Honours for services to charity, entertainment and the arts. David Littman (activist) (4 July 1933 – 20 May 2012) author of over five books and scores of monographs and academic papers and activist best known for organising the departure of Jewish children from Morocco; then worked as lobbyist at the United Nations in Geneva and was also historian. He was married to Bat Ye'or. Emanuel Litvinoff, novelist. (5 May 1915 – 24 September 2011) was a British writer and well-known figure in Anglo-Jewish literature, known for novels, short stories, poetry, plays and human rights campaigning. Litvinoff became aware of plight of persecuted Soviet Jews, and started worldwide campaign against this persecution. Due to Litvinoff's efforts, prominent Jewish groups in United States became aware of issue, and well-being of Soviet Jews became cause for a worldwide campaign, eventually leading to mass migration of Jews from the Soviet Union to Israel and the United States. For this he has been described by Meir Rosenne, former Israeli ambassador to the United States, as "one of the greatest unsung heroes of the twentieth century... who won in the fight against an evil empire" and that "thousands and thousands of Russian Jews owe him their freedom".
Liver Function Tests at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Liver Function Tests at Lab Tests Online Overview at Mayo Clinic Abnormal Liver Function Tests Archived 11 April 2012 at the Wayback Machine Overview of liver enzymes Abnormal Liver Tests Curriculum at AASLD Further workup of abnormal liver tests: "etiology panel"
Based on a 2002 crystal structure analysis, α-amanitin interacts with the bridge helix in RNA polymerase II (pol II). This interaction interferes with the translocation of RNA and DNA needed to empty the site for the next round of RNA synthesis. The addition of α-amanitin can reduce the rate of pol II translocating on DNA from several thousand to a few nucleotides per minute, but has little effect on the affinity of pol II for nucleoside triphosphate, and a phosphodiester bond can still be formed. The bridge helix has evolved to be flexible and its movement is required for translocation of the polymerase along the DNA backbone. Binding of α-amanitin puts a constraint on its mobility, hence slowing down the translocation of the polymerase and the rate of synthesis of the RNA molecule.
Sources: en.wikipedia.org
=== Structure activity relationship === The structure of Benzoquinones may explain their toxicity. Benzoquinones are electrophilic and can undergo reactions with nucleophilic groups, for instance on amino acids, altering structure and function of the proteins. Due to the Cl groups on the quinone ring in DCBQ, the overall electrophilicity of the HBQ is increased, which causes higher reactivity with nucleophilic groups, such as glutathione, proteins, and nucleic acids. If DCBQ reacts with glutathione they form conjugates, lowering GSH levels in the cell, which might lead to GSH depletion.
During the 2024 presidential election, Moore was a member of the Biden-Harris Campaign National Advisory Board and campaigned for President Joe Biden in Wisconsin and Georgia. He also defended Biden from calls to drop out of the presidential election amid the first 2024 presidential debate, highlighting Biden's accomplishments in office while conceding that the debate was a "rough night" for the president. After Biden withdrew from the race on July 21, 2024, Moore endorsed and campaigned for Vice President Kamala Harris. During the 2024 United States Senate election in Maryland, Moore endorsed Prince George's County Executive Angela Alsobrooks in the Democratic primary over U.S. representative David Trone. He played an active role in campaigning against Republican nominee and former governor Larry Hogan in the general election, with several of his top advisors leaving their positions in the Moore administration to form a political action committee called Unity First PAC to support Alsobrooks and other Democratic nominees downballot.
Because of the botched living donor kidney transplant at UPMC, the federal Organ Procurement Transplant Network (OPTN) put UPMC's transplant program on probation, a rarely used form of discipline handed down for some of the most serious transplant errors. The OPTN said it meted out the discipline not only because of the kidney transplant error, but because UPMC's transplant program was found to have problems in its communication and documentation procedures before. In April 2009, rival West Penn Allegheny Health System filed an antitrust lawsuit against the UPMC and health insurer Highmark, claiming a conspiracy to create a monopoly. The lawsuit was later dismissed with prejudice. West Penn Allegheny filed an appeal of this judgment. Upon appeal, the case was unanimously reinstated by the US Third Circuit Court of Appeals. In October 2009, UPMC's administration decision to close UPMC Braddock hospital resulted in multiple protest and lawsuits by community groups who disputed UPMC's claims that the hospital was losing money and was underutilized. The facility, now demolished in preparation for redevelopment, closed in January 2010. In April 2013, UPMC has been criticized for paying low wages, and using unfair labor practices to thwart efforts by employees to unionize, as alleged in the Service Employees International Union's complaint to the National Labor Relations Board. In addition, critics have accused the system of using noncompete agreements, preventing workers from mobilizing, and suppressing wages.
Sources: en.wikipedia.org
=== Kits === The modern-day interest in absinthe has spawned a rash of absinthe kits from sellers claiming they produce homemade absinthe. Kits often call for soaking herbs in vodka or alcohol or adding a liquid concentrate to vodka or alcohol to create an ersatz absinthe. Such practices usually yield a harsh substance that bears little resemblance to the genuine article and is considered inauthentic by any practical standard. Some concoctions may even be dangerous, especially if they call for a potentially poisonous inclusion of herbs, oils, or extracts. In at least one documented case, a person suffered acute kidney injury after drinking 10 ml of pure wormwood oil.
Yuchanyan is an early Neolithic cave site in Dao County (Daoxian), Hunan, China. The site yielded sherds of ceramic vessels and other artifacts which were dated by analysis of charcoal and bone collagen, giving a date range of 17,500 to 18,300 years old for the pottery. The pottery specimens may be the oldest known examples of pottery. The cave yielded fragmentary remains of 2 or more ceramic vessels, in addition to large amounts of ash, a rich animal bone assemblage, cobble and flake artifacts, bone tools, and shell tools. The artifacts indicate that the cave was a Late Paleolithic foragers' camp. Here we report on the radiocarbon ages of the sediments based on analyses of charcoal and bone collagen. The best-preserved charcoal and bone samples were identified by prescreening in the field and laboratory. The dates range from around 21,000 to 13,800 cal BP. The age of the ancient pottery ranges between 18,300 and 15,430 cal BP. Charcoal and bone collagen samples located above and below one of the fragments produced dates of around 18,000. These ceramic potsherds therefore provide some of the earliest evidence for pottery making in China.
Because the risks of warfarin – which is used to treat blood clots – in a relatively young and otherwise healthy population are low, while the risk of adverse physical and psychological outcomes for untreated transgender patients is high, prothrombotic mutations (such as factor V Leiden, antithrombin III, and protein C or S deficiency) are not absolute contraindications for hormonal therapy. A 2018 cohort study of 2842 transfeminine individuals in the United States treated with a mean follow-up of 4.0 years observed an increased risk of VTE, stroke, and heart attack relative to a cisgender reference population. The estrogens used included oral estradiol (1 to 10 mg/day) and other estrogen formulations. Other medications such as antiandrogens like spironolactone were also used. A 2025 Dutch retrospective cohort study reported lower or similar risks for arterial cardiovascular events, but an elevated risk of venous thromboembolism. In 2,714 transgender women receiving gender-affirming hormone therapy, with 23,907 person-years of follow-up during the observation period, the study found that after adjustment for socioeconomic status, transgender women had a lower risk of myocardial infarction, a similar risk of ischaemic cerebrovascular accident, and a higher risk of venous thromboembolism compared with general-population men. A 2019 systematic review and meta-analysis found an incidence rate of VTE of 2.3 per 1000 person-years with feminizing hormone therapy in transgender women.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.